Drugs / CBT-1
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03002805 | Mar 2018 → Sep 2020 | sarcoma | CBA Research | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00972205 | Dec 2007 → Jun 2009 | breast disorder, cervix disorder, lung disorder, ovarian disorder | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT00437749 Comparator | Aug 2001 → Jul 2010 | non-small cell lung carcinoma | CBA Research | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CBT-1 | “CBT-1® is an orally administered bisbenzylisoquinoline Pgp inhibitor being evaluated clinically.” PMID 22416063 ↗ Mar 2012 |
| Action | Inhibit | “CBT-1 is a natural product currently in clinical trials as an inhibitor” NCT00437749 ↗ |
| Modality | Small molecule | “CBT-1® is an orally administered bisbenzylisoquinoline Pgp inhibitor being evaluated clinically.” PMID 22416063 ↗ Mar 2012 |
| Route | Oral | “CBT-1 500 mg/m\^2 oral dose daily for 7 days in divided doses 3 times a day.” NCT00972205 ↗ |